Immix Biopharma Inc (IMMX) Financials

$13.91

$0.08 (0.58%)

As on 04-Sep-2026 17:05EDT

Market cap

$990 Mln

Revenue (TTM)

$0 Mln

P/E Ratio

--

P/B Ratio

4.4

Div. Yield

0 %

Annual
Quarterly

Income Statement ($ Mln)	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Operating Revenue	--	--	--	--	-89.52	--
Cost of Revenue	0.22	0.36	0.12	0.01	0.00	0.00
Gross Profit	-0.22	-0.36	-0.12	-0.01	-89.52	0.00
Operating Expenses	41.82	29.96	22.67	16.14	8.22	1.35
Operating Profit (EBIT)	-41.82	-29.96	-22.67	-16.14	-8.22	-1.35
Other Income	--	--	--	--	--	--
Profit before Tax	-39.88	-29.40	-21.66	-15.57	-8.22	-24.38
Provision for Tax	0.03	0.04	0.04	0.03	0.01	0.01
Profit after Tax (Net Income)	-39.92	-29.44	-21.61	-15.43	-8.23	-24.38
Minority Interest	--	--	0.08	0.17	--	--
Consolidated Profit	--	--	--	--	-8.23	-24.38

Liabilities ($ Mln)	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Shareholder's Funds	228.92	93.80	13.25	16.41	13.16	17.99
Minority Interest	--	--	--	--	--	--
Non-Current Liabilities	0.89	0.93	1.01	--	0.48	0.19
Current Liabilities	9.30	10.11	8.69	3.72	1.27	0.20
Total Liabilities	248.41	104.84	22.95	19.93	14.91	18.19

Assets ($ Mln)	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Non-Current Assets	5.32	3.60	2.75	0.14	0.01	0.01
Current Assets	233.79	101.24	20.20	19.79	14.90	18.19
Total Assets	248.41	104.84	22.95	19.93	14.91	18.19
Total Debt*	1.00	1.07	1.07	--	--	0.05
Net Current Assets	224.49	91.13	11.51	16.07	13.62	17.98

Cashflow ($ Mln)	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Cash From Operating Activities	--	-23.93	-14.60	-11.37	-7.41	-1.59
Cash Flow from Investing Activities	--	-7.21	-1.18	-0.05	--	0.00
Cash from Financing Activities	--	107.39	15.95	15.46	3.23	18.85
Net Cash Inflow / Outflow	--	--	--	--	--	--

Financials Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Adjusted EPS ($)	-0.88	-0.77	-0.78	-0.77	-0.62	-3.22
Cash EPS ($)	--	-0.76	-0.78	-0.77	-0.62	-3.22
Adjusted Book Value ($)	--	2.45	0.48	0.82	0.99	2.37
Dividend per Share ($)	--	--	--	--	--	--
Cash Flow per Share ($)	--	-0.63	-0.53	-0.57	-0.56	-0.21
Free Cash Flow per Share ($)	--	-0.64	-0.57	-0.57	-0.56	-0.21

Profitability Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
ROCE (%)	--	-53.92	-140.66	-104.35	-52.75	-280.12
ROE (%)	-24.74	-55.00	-145.76	-104.35	-52.84	-367.80
ROA (%)	-29.13	-46.07	-100.83	-88.57	-49.73	-260.35
EBIT Margin (%)	--	--	--	--	9.18	--
Net Margin (%)	--	--	--	--	9.19	--
Cash Profit Margin (%)	--	--	--	--	--	--

Growth Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Revenue Growth (%)	--	--	--	1.00	--	--
EBIT Growth (%)	-25.87	-38.32	-39.10	-89.43	66.03	-5,231.70
Net Profit Growth (%)	-72.60	-36.21	-40.11	-87.44	66.25	-2,024.28
EPS Growth (%)	-11.20	0.02	-0.01	-0.24	0.81	-20.24
Book Value Growth (%)	2,213.14	--	--	--	--	--

Valuation Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Price / Earnings	--	-6.80	-2.80	-8.94	-3.68	-1.11
Price / Book Value	4.36	2.13	4.57	8.40	2.30	1.50
Dividend Yield (%)	--	--	--	--	--	--
EV/EBITDA	-0.37	-3.41	-2.04	-7.73	-2.05	-0.39
Close Price ($)	10.31	5.23	2.20	6.92	2.29	3.56
High Price ($)	11.61	7.73	6.88	7.75	8.68	6.31
Low Price ($)	1.94	1.34	1.26	1.40	0.68	2.85
Market Cap ($ Cr)	990.25	--	--	--	--	--

Solvency Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Debt to Equity	--	0.01	0.08	--	--	0.00
Short term debt to equity ratio	0.00	0.00	0.00	--	--	0.00
Current Ratio	25.13	10.01	2.33	5.32	11.70	90.01
Quick Ratio	25.13	--	--	--	--	--
Interest Coverage	--	--	--	--	-16,537.12	-134.54

Operating Efficiency Ratios	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Debtors to sales (%)	--	--	--	--	-0.29	--
Asset Turnover	--	--	--	--	-5.41	--
Receivable days	--	--	--	--	-0.57	--
Inventory Days	--	--	--	--	--	--
Payable days	--	5,426.74	10,796.44	52,639.82	24,465.25	29,249.89
Cash Conversion Cycle	--	--	--	--	--	--

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.